The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients

Chemotherapy

Volumn 53, Issue 2, 2007, Pages 127-131

  Zhou, Zhi Wei ^a   Wang, Guo Qiang ^a   Wan, De Sen ^a   Lu, Zhen Hai ^a   Chen, Ying Bo ^a   Li, Su ^a   Chen, Gong ^a   Pan, Zhi Zhong ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

5 Fluorouracil associated toxicity; Colorectal cancer; Dihydropyrimidine dehydrogenase; Dihydrouracil; Uracil

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; DIHYDROURACIL; FLUOROURACIL; FOLINIC ACID; URACIL;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW DEPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CORRELATION ANALYSIS; DIARRHEA; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; URACIL; VITAMIN B COMPLEX;

EID: 33847721425     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000099984     Document Type: Article

References (19)

1. Schiavon G, Vincenzi B, Santini D, Avvisati G, Tonini G: Recurrent thrombophlebitis in a colon cancer patient with C677T heterozygous genotype for MTHFR treated with 5-fluorouracil-based adjuvant chemotherapy. Chemotherapy 2004;50:194-195.
2. Barutca S, Ceyhan C, Meydan N, Ozturk B, Tekten T, Onbasili A, Kadikoylu G, Bolaman Z: A new perspective on cardiotoxicity of 5-fl uorouracil. A novel research tool 'cardiac ultrasonic integrated backscatter analysis' indicates transient, subclinical myocardial dysfunction due to high-dose leucovorin and infusional 5-fluorouracil regimen. Chemotherapy 2004;50:113-118.
3. Yang TS, Chen JS, Tang R, Chiang JM, Hsieh PS, Yeh CY, Changchien CR: Oxaliplatin with weekly bolus 5-fluorouracil and leucovorin in pretreated advanced colorectal cancer patients: a phase II study. Chemotherapy 2003;49:194-199.
4. Johnson MR, Wang K, Diasio RB: Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 2002;8:768-774.
5. Katona C, Kralovanszky J, Rosta A, Pandi E, Fonyad G, Toth K, Jeney A: Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients. Oncology 1998;55:468-474.
6. Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Renee N: Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 1999;79:627-630.
7. Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB: Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 1999;5:2006-2011.
8. van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA, Maring JG, Vreken P, van Gennip AH: Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000;6:4705-4712.
9. Raida M, Schwabe W, Hausler P, Van Kuilenburg AB, Van Gennip AH, Behnke D, Hoffken K: Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 50-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 2001;7:2832-2839.
10. van Kuilenburg AB: Dihydropyrimidine dehydrogenase and efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004;40:939-950.
11. Gamelin E, Boisdron-Celle M, Larra F, Robert J: A simple chromatographic method for the analysis of pyrimidines and their dehydrogenated metabolites. J Liq Chrom Relat Technol 1997;20:3155-3172.
12. Gamelin E, Boisdron-Celle M, Turcant A, Allain P, Robert J: Rapid and sensitive liquid chromatographic analysis of halogenopyrimidines in plasma. J Chromatogr B 1997;695:409-416.
13. Common Toxicity Criteria. National Cancer Institute, version 2.0, April 30, 1999.
14. McLeod HL, Sludden J, Murray GI, Keenan RA, Davidson AI, Park K, Koruth M, Cassidy J: Characterization of dihydropyrimidine dehydrogenase in human colorectal tumors. Br J Cancer 1998;77:461-465.
15. Lu ZH, Zhang RW, Robert BD: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993;53:5433-5438.
16. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N, Schneider M, Demard F, Milano G: Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994;12:2248-2253.
17. Uetake H, Ichikawa W, Takechi T, Fukushima M, Nihei Z, Sugihara K: Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer. Clin Cancer Res 1999;5:2836-2839.
18. Gamelin E, Boisdron-Celle M, Guerin-Meyer V, Delva R, Lortholary A, Genevieve F, Larra F, Ifrah N, Robert J: Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 1999;17:1105-1110.
19. Harris BE, Song R, Soong SJ, Diasio RB: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990;50:197-201.